These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 12876904)

  • 21. Resistance of uropathogens in symptomatic urinary tract infections in León, Nicaragua.
    Matute AJ; Hak E; Schurink CA; McArthur A; Alonso E; Paniagua M; Van Asbeck E; Roskott AM; Froeling F; Rozenberg-Arska M; Hoepelman IM
    Int J Antimicrob Agents; 2004 May; 23(5):506-9. PubMed ID: 15120732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model.
    Bantar C; Canigia LF; Berger MA; Soutric JL; Arenoso HJ
    Braz J Infect Dis; 2009 Oct; 13(5):348-52. PubMed ID: 20428633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae.
    Bantar C; Nicola F; Arenoso H; Soutric J; Caruso N; Fernández Canigia L
    J Chemother; 2004 Jun; 16(3):248-54. PubMed ID: 15330320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
    Shungu DL; Ponticas S; Gill CJ
    Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model.
    Bantar C; Fernandez Canigia L; Berger MA; Soutric JL; Arenoso HJ
    J Chemother; 2009 Jun; 21(3):296-301. PubMed ID: 19567350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections.
    Casellas JM; Tome G; Exeni R; Grimoldi I; Goldberg M; Farinati AE
    Pathol Biol (Paris); 1993 Apr; 41(4):385-91. PubMed ID: 8233640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli.
    Stein GE; Schooley SL; Nicolau DP
    Int J Antimicrob Agents; 2008 Oct; 32(4):320-5. PubMed ID: 18715762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibacterial activity of ofloxacin in urine for 4 days after a single oral dose of 400 mg].
    Guibert J; Kitzis MD; Acar JF
    Pathol Biol (Paris); 1998 Oct; 46(8):656-60. PubMed ID: 9871938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.
    Hofbauer H; Naber KG; Kinzig-Schippers M; Sörgel F; Rustige-Wiedemann C; Wiedemann B; Reiz A; Kresken M
    Infection; 1997; 25(2):121-6. PubMed ID: 9108190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Resistance of Escherichia coli isolated from the urinary tract to amoxicillin-clavulanic acid and other antibiotics].
    Ferjani A; Marzouk M; Ben Moussa F; Boukadida J
    Med Mal Infect; 2010 Mar; 40(3):161-4. PubMed ID: 19616395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.
    Lamp KC; Vickers MK
    Antimicrob Agents Chemother; 1998 Feb; 42(2):231-5. PubMed ID: 9527765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
    Jakobsen L; Cattoir V; Jensen KS; Hammerum AM; Nordmann P; Frimodt-Møller N
    J Antimicrob Chemother; 2012 Oct; 67(10):2438-44. PubMed ID: 22685162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
    Moittie D; Simonet M; Veron M
    Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of sultamicillin in the treatment of urinary tract infections].
    Fukatsu H; Noonmura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Yamada Y; Segawa A
    Hinyokika Kiyo; 1990 Jul; 36(7):861-7. PubMed ID: 2239586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
    Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
    J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A comparison of the in vitro susceptibility of three bacteria to beta-lactamase inhibitors and to ampicillin and cefazolin].
    Acar N; Diri MC; Türkyilmaz FR
    Mikrobiyol Bul; 1987 Oct; 21(4):284-8. PubMed ID: 3332705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of catheter-associated urinary tract infections and multi-drug-resistant Escherichia coli isolates from the urine of dogs with indwelling urinary catheters.
    Ogeer-Gyles J; Mathews K; Weese JS; Prescott JF; Boerlin P
    J Am Vet Med Assoc; 2006 Nov; 229(10):1584-90. PubMed ID: 17107313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro and in vivo activity of a combination of clavulanic acid and amoxicillin against Klebsiella pneumoniae producing extended broad-spectrum betalactamase (CTX-1, SHV-3, SHV-4)].
    Migueres ML; Ronco E; Guenounou M; Philippon A
    Pathol Biol (Paris); 1989 May; 37(5):397-401. PubMed ID: 2674869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
    Gill CJ; Ponticas S; Shungu DL; Guerriero S
    Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.